313 related articles for article (PubMed ID: 25516478)
1. Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.
Berrien-Elliott MM; Yuan J; Swier LE; Jackson SR; Chen CL; Donlin MJ; Teague RM
Cancer Immunol Res; 2015 Feb; 3(2):116-24. PubMed ID: 25516478
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
4. High Levels of Eomes Promote Exhaustion of Anti-tumor CD8
Li J; He Y; Hao J; Ni L; Dong C
Front Immunol; 2018; 9():2981. PubMed ID: 30619337
[TBL] [Abstract][Full Text] [Related]
5. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
6. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y; Trillo-Tinoco J; Sierra RA; Anadon C; Dai W; Mohamed E; Cen L; Costich TL; Magliocco A; Marchion D; Klar R; Michel S; Jaschinski F; Reich RR; Mehrotra S; Cubillos-Ruiz JR; Munn DH; Conejo-Garcia JR; Rodriguez PC
Nat Commun; 2019 Mar; 10(1):1280. PubMed ID: 30894532
[TBL] [Abstract][Full Text] [Related]
7. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
9. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses.
Zhu Y; Ju S; Chen E; Dai S; Li C; Morel P; Liu L; Zhang X; Lu B
J Immunol; 2010 Sep; 185(6):3174-83. PubMed ID: 20713880
[TBL] [Abstract][Full Text] [Related]
10. T-Bet and Eomes Regulate the Balance between the Effector/Central Memory T Cells versus Memory Stem Like T Cells.
Li G; Yang Q; Zhu Y; Wang HR; Chen X; Zhang X; Lu B
PLoS One; 2013; 8(6):e67401. PubMed ID: 23826287
[TBL] [Abstract][Full Text] [Related]
11. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.
Wang L; Amoozgar Z; Huang J; Saleh MH; Xing D; Orsulic S; Goldberg MS
Cancer Immunol Res; 2015 Sep; 3(9):1030-41. PubMed ID: 26056145
[TBL] [Abstract][Full Text] [Related]
12. Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype.
Jackson SR; Berrien-Elliott M; Yuan J; Hsueh EC; Teague RM
PLoS One; 2014; 9(10):e110707. PubMed ID: 25343644
[TBL] [Abstract][Full Text] [Related]
13. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
[TBL] [Abstract][Full Text] [Related]
14. Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
Makkouk A; Joshi VB; Lemke CD; Wongrakpanich A; Olivier AK; Blackwell SE; Salem AK; Weiner GJ
Cancer Immunol Res; 2015 Apr; 3(4):389-98. PubMed ID: 25627654
[TBL] [Abstract][Full Text] [Related]
15. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
16. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
17. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling.
Grange M; Verdeil G; Arnoux F; Griffon A; Spicuglia S; Maurizio J; Buferne M; Schmitt-Verhulst AM; Auphan-Anezin N
J Immunol; 2013 Oct; 191(7):3712-24. PubMed ID: 24006458
[TBL] [Abstract][Full Text] [Related]
18. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
[TBL] [Abstract][Full Text] [Related]
19. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
20. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
